NLRP3 Inflammasome: Activation and Regulation in Age-Related Macular Degeneration

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Gao, Jiangyuan ^a   Liu, Ruozhou Tom ^a   Cao, Sijia ^a   Cui, Jing Z ^a   Wang, Aikun ^a   To, Eleanor ^a   Matsubara, Joanne A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLAMMASOME; NLRP3 INFLAMMASOME; UNCLASSIFIED DRUG; CARRIER PROTEIN; CRYOPYRIN; NLRP3 PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MITOCHONDRION; PIGMENT EPITHELIUM; PRIORITY JOURNAL; REVIEW; UBIQUITINATION; ANIMAL; BRUCH MEMBRANE; MACULAR DEGENERATION; METABOLISM; PATHOLOGY; RETINAL PIGMENT EPITHELIUM;

ANIMALS; BRUCH MEMBRANE; CARRIER PROTEINS; HUMANS; INFLAMMASOMES; MACULAR DEGENERATION; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; RETINAL PIGMENT EPITHELIUM;

EID: 84934284610     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/690243     Document Type: Review

References (113)

1. J. Ambati, J. P. Atkinson, and B. D. Gelfand, "Immunology of age-related macular degeneration," Nature Reviews Immunology, vol. 13, no. 6, pp. 438-451, 2013.
2. World-Health-Organization, "Age-related macular degeneration," in Prevention of Blindness and Visual Impairment- Priority Eye Diseases,World-Health-Organization, 2014, http:// www.who.int/blindness/causes/priority/en/index7.html.
3. Access-Economics, "The global economic cost of visual impairment," http://www.icoph.org/resources/146/The-Global-Economic- Cost-of-Visual-Impairment.html.
4. D. S. Friedman, J. Katz, N. M. Bressler, B. Rahmani, and J. M. Tielsch, "Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey," Ophthalmology, vol. 106, no. 6, pp. 1049-1055, 1999.
5. K. J. Cruickshanks, R. Klein, and B. F. K. Klein, "Sunlight and age-related macular degeneration.The Beaver Dam Eye Study," Archives of Ophthalmology, vol. 111, no. 4, pp. 514-518, 1993.
6. J. R. Vingerling, I. Dielemans, A. Hofman et al., "The prevalence of age-related maculopathy in the Rotterdam study," Ophthalmology, vol. 102, no. 2, pp. 205-210, 1995.
7. D. S. Friedman, B. J. O'Colmain, B. Muñoz et al., "Prevalence of age-relatedmacular degeneration in theUnited States," Archives of Ophthalmology, vol. 122, no. 4, pp. 564-572, 2004.
8. Age-Related Eye Disease Study Research Group, "A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for agerelated macular degeneration and vision loss: AREDS report no. 8," Archives of Ophthalmology, vol. 119, no. 10, pp. 1417-1436, 2001.
9. "Age-related eye disease study 2 researchG. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial," The Journal of the American Medical Association, vol. 309, no. 19, pp. 2005-2015, 2013.
10. E.Y. Chew, T. E. Clemons, E. Agrón et al., "Long-termeffects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS Report No. 35," Ophthalmology, vol. 120, no. 8, pp. 1604.e4-1611.e4, 2013.
11. A. Woodell and B. Rohrer, "A mechanistic review of cigarette smoke and age-relatedmacular degeneration," in RetinalDegenerative Diseases, vol. 801 of Advances in Experimental Medicine and Biology, pp. 301-307, Springer, New York, NY, USA, 2014.
12. S. L. Fine, J. W. Berger, M. G. Maguire, and A. C. Ho, "Agerelated macular degeneration," The New England Journal of Medicine, vol. 342, no. 7, pp. 483-492, 2000.
13. M. Boulton and P. Dayhaw-Barker, "The role of the retinal pigment epithelium: topographical variation and ageing changes," Eye, vol. 15, part 3, pp. 384-389, 2001.
14. O. Strauss, "The retinal pigment epithelium in visual function," Physiological Reviews, vol. 85, no. 3, pp. 845-881, 2005.
15. D. H. Anderson, R. F. Mullins, G. S. Hageman, and L. V. Johnson, "A role for local inflammation in the formation of drusen in the aging eye," American Journal of Ophthalmology, vol. 134, no. 3, pp. 411-431, 2002.
16. M. L. Klein, F. L. Ferris III, J. Armstrong et al., "Retinal precursors and the development of geographic atrophy in agerelated macular degeneration," Ophthalmology, vol. 115, no. 6, pp. 1026-1031, 2008.
17. W. A. Tseng, T. Thein, K. Kinnunen et al., "NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration," Investigative Ophthalmology and Visual Science, vol. 54, no. 1, pp. 110-120, 2013.
18. S. L. Doyle, M. Campbell, E. Ozaki et al., "NLRP3 has a protective role in age-relatedmacular degeneration through the induction of IL-18 by drusen components," Nature Medicine, vol. 18, no. 5, pp. 791-798, 2012.
19. R. T. Liu, A. Wang, E. To et al., "Vinpocetine inhibits amyloid- β induced activation of NF-κB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells," Experimental Eye Research, vol. 127, pp. 49-58, 2014.
20. N. Kerur, Y. Hirano, V. Tarallo et al., "TLR-independent and P2X7-dependent signaling mediate Alu RNA-induced NLRP3 inflammasome activation in geographic atrophy," Investigative Ophthalmology & Visual Science, vol. 54, no. 12, pp. 7395-7401, 2013.
21. O. A. Anderson, A. Finkelstein, and D. T. Shima, "A2E induces IL-1ss production in retinal pigment epithelial cells via the NLRP3 inflammasome," PLoS ONE, vol. 8, no. 6, Article ID e67263, 2013.
22. A. Kauppinen, H. Niskanen, T. Suuronen, K. Kinnunen, A. Salminen, and K. Kaarniranta, "Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells-implications for agerelatedmacular degeneration (AMD)," Immunology Letters, vol. 147, no. 1-2, pp. 29-33, 2012.
23. A. Halle, V. Hornung, G. C. Petzold et al., "The NALP3 inflammasome is involved in the innate immune response to amyloid- β," Nature Immunology, vol. 9, no. 8, pp. 857-865, 2008.
24. E. Asgari, G. Le Friec, H. Yamamoto et al., "C3a modulates IL- 1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation," Blood, vol. 122, no. 20, pp. 3473-3481, 2013.
25. F. Laudisi, R. Spreafico, M. Evrard et al., "Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release," Journal of Immunology, vol. 191, no. 3, pp. 1006-1010, 2013.
26. B. F. Py, M.-S. Kim, H. Vakifahmetoglu-Norberg, and J. Yuan, "Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity," Molecular Cell, vol. 49, no. 2, pp. 331-338, 2013.
27. M.A. Rodgers, J.W. Bowman, H. Fujita et al., "The linear ubiquitin assembly complex (LUBAC) is essential for NLRP3 inflammasome activation,"The Journal of Experimental Medicine, vol. 211, no. 7, pp. 1333-1347, 2014.
28. S. Camelo, "Potential sources and roles of adaptive immunity in age-related macular degeneration: shall we rename AMD into autoimmune macular disease?" Autoimmune Diseases, vol. 2014, Article ID532487, 11 pages, 2014.
29. A. Iannaccone, I. Neeli, P. Krishnamurthy et al., "Autoimmune biomarkers in age-relatedmacular degeneration: a possible role player in disease development and progression," Advances in Experimental Medicine and Biology, vol. 723, pp. 11-16, 2012.
30. P. Menu and J. E. Vince, "The NLRP3 inflammasome in health and disease: the good, the bad and the ugly," Clinical and Experimental Immunology, vol. 166, no. 1, pp. 1-15, 2011.
31. M. Lamkanfi, L. V. Walle, and T.-D. Kanneganti, "Deregulated inflammasome signaling in disease," Immunological Reviews, vol. 243, no. 1, pp. 163-173, 2011.
32. B. K. Davis, H. Wen, and J. P.-Y. Ting, "The Inflammasome NLRs in immunity, inflammation, and associated diseases," Annual Review of Immunology, vol. 29, pp. 707-735, 2011.
33. L. Franchi, T. Eigenbrod, R. Muñoz-Planillo, and G. Nuñez, "The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis," Nature Immunology, vol. 10, no. 3, pp. 241-247, 2009.
34. M. Lamkanfi and V. M. Dixit, "Mechanisms and functions of inflammasomes," Cell, vol. 157, no. 5, pp. 1013-1022, 2014.
35. N. Kayagaki, S. Warming, M. Lamkanfi et al., "Non-canonical inflammasome activation targets caspase-11," Nature, vol. 479, no. 7371, pp. 117-121, 2011.
36. K. E. Lawlor and J. E. Vince, "Ambiguities in NLRP3 inflammasome regulation: is there a role for mitochondria?" Biochimica et Biophysica Acta-General Subjects, vol. 1840, no. 4, pp. 1433-1440, 2014.
37. F. S. Sutterwala, S. Haasken, and S. L. Cassel, "Mechanism of NLRP3 inflammasome activation," Annals of the New York Academy of Sciences, vol. 1319, no. 1, pp. 82-95, 2014.
38. F. G. Bauernfeind, G. Horvath, A. Stutz et al., "Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression,"The Journal of Immunology, vol. 183, no. 2, pp. 787-791, 2009.
39. S. L. Doyle, E. Ozaki, K. Brennan et al., "IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration," Science Translational Medicine, vol. 6, no. 230,Article ID 230ra44, 2014.
40. V. Tarallo,Y. Hirano, B. D. Gelfand et al., "DICER1 loss andAlu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88," Cell, vol. 149, no. 4, pp. 847-859, 2012.
41. C. Juliana, T. Fernandes-Alnemri, S. Kang, A. Farias, F. Qin, and E. S. Alnemri, "Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation," Journal of Biological Chemistry, vol. 287, no. 43, pp. 36617-36622, 2012.
42. F. di Virgilio, "The therapeutic potential of modifying inflammasomes and NOD-like receptors," Pharmacological Reviews, vol. 65, no. 3, pp. 872-905, 2013.
43. R. Muñoz-Planillo, P. Kuffa, G. Marti´nez-Colón, B. L. Smith, T. M. Rajendiran, and G. Núñez, "K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter," Immunity, vol. 38, no. 6, pp. 1142-1153, 2013.
44. V. Hornung, F. Bauernfeind, A. Halle et al., "Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization," Nature Immunology, vol. 9, no. 8, pp. 847-856, 2008.
45. R. Zhou, A. S. Yazdi, P. Menu, and J. Tschopp, "A role for mitochondria in NLRP3 inflammasome activation," Nature, vol. 469, no. 7329, pp. 221-225, 2011.
46. T. Misawa, M. Takahama, T. Kozaki et al., "Microtubule-driven spatial arrangement ofmitochondria promotes activation of the NLRP3 inflammasome," Nature Immunology, vol. 14, no. 5, pp. 454-460, 2013.
47. J. W. Crabb, M. Miyagi, X. Gu et al., "Drusen proteome analysis: an approach to the etiology of age-related macular degeneration," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 23, pp. 14682-14687, 2002.
48. R. F. Mullins, S. R. Russell, D. H. Anderson, and G. S. Hageman, "Drusen associated with aging and age-relatedmacular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease," The FASEB Journal, vol. 14, no. 7, pp. 835-846, 2000.
49. G. S. Hageman, P. J. Luthert, N. H. V. Chong, L. V. Johnson, D. H. Anderson, and R. F. Mullins, "An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch'smembrane interface in aging and age-related macular degeneration," Progress in Retinal and Eye Research, vol. 20, no. 6, pp. 705-732, 2001.
50. L. V. Johnson,W. P. Leitner, M. K. Staples, and D. H. Anderson, "Complement activation and inflammatory processes in drusen formation and age related macular degeneration," Experimental Eye Research, vol. 73, no. 6, pp. 887-896, 2001.
51. L. V. Johnson, W. P. Leitner, A. J. Rivest, M. K. Staples, M. J. Radeke, and D. H. Anderson, "The Alzheimer's A β-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 18, pp. 11830-11835, 2002.
52. M. Nozaki, B. J. Raisler, E. Sakurai et al., "Drusen complement components C3a and C5a promote choroidal neovascularization," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2328-2333, 2006.
53. T. Dentchev, A. H. Milam, V. M. Y. Lee, J. Q. Trojanowski, and J. L. Dunaief, "Amyloid-beta is found in drusen from some agerelated macular degeneration retinas, but not in drusen from normal retinas," Molecular Vision, vol. 9, pp. 184-190, 2003.
54. V. Luibl, J.M. Isas, R. Kayed, C.G. Glabe, R. Langen, and J. Chen, "Drusendeposits associatedwith aging and age-relatedmacular degeneration contain nonfibrillar amyloid oligomers," Journal of Clinical Investigation, vol. 116, no. 2, pp. 378-385, 2006.
55. D. Mevorach, "Clearance of dying cells and systemic lupus erythematosus: the role of C1q and the complement system," Apoptosis, vol. 15, no. 9, pp. 1114-1123, 2010.
56. D. H. Anderson, M. J. Radeke, N. B. Gallo et al., "The pivotal role of the complement systemin aging and age-relatedmacular degeneration: hypothesis re-visited," Progress in Retinal and Eye Research, vol. 29, no. 2, pp. 95-112, 2010.
57. S. Khandhadia, V. Cipriani, J. R.W. Yates, andA. J. Lotery, "Agerelated macular degeneration and the complement system," Immunobiology, vol. 217, no. 2, pp. 127-146, 2012.
58. K. Triantafilou, T. R. Hughes, M. Triantafilou, and P. Morgan, "The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation," Journal of Cell Science, vol. 126, no. 13, pp. 2903-2913, 2013.
59. D. H. Anderson, K. C. Talaga, A. J. Rivest, E. Barron, G. S. Hageman, and L. V. Johnson, "Characterization of β amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration," Experimental Eye Research, vol. 78, no. 2, pp. 243-256, 2004.
60. J. M. Isas, V. Luibl, L. V. Johnson et al., "Soluble and mature amyloid fibrils in drusen deposits," Investigative Ophthalmology and Visual Science, vol. 51, no. 3, pp. 1304-1310, 2010.
61. C. Haass and D. J. Selkoe, "Soluble protein oligomers in neurodegeneration: lessons fromthe Alzheimer's amyloid β-peptide," Nature Reviews Molecular Cell Biology, vol. 8, no. 2, pp. 101-112, 2007.
62. N. Iwata, S. Tsubuki, Y. Takaki et al., "Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition," Nature Medicine, vol. 6, no. 2, pp. 143-150, 2000.
63. R. Madani, R. Poirier, D. P. Wolfer et al., "Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo," Journal of Neuroscience Research, vol. 84, no. 8, pp. 1871-1878, 2006.
64. R. Kayed, E. Head, J. L. Thompson et al., "Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis," Science, vol. 300, no. 5618, pp. 486-489, 2003.
65. D. M. Walsh, I. Klyubin, J. V. Fadeeva et al., "Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo," Nature, vol. 416, no. 6880, pp. 535-539, 2002.
66. W. L. Klein, G. A. Krafft, and C. E. Finch, "Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?" Trends in Neurosciences, vol. 24, no. 4, pp. 219-224, 2001.
67. M.D. Kirkitadze, G. Bitan, and D.B. Teplow, "Paradigmshifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies," Journal ofNeuroscience Research, vol. 69, no. 5, pp. 567-577, 2002.
68. B. Caughey and P. T. Lansbury Jr., "Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders," Annual Review of Neuroscience, vol. 26, pp. 267-298, 2003.
69. R. T. Liu, J. Gao, S. Cao et al., "Inflammatorymediators induced by amyloid-beta in the retina and RPE in vivo: implications for inflammasome activation in age-relatedmacular degeneration," Investigative Ophthalmology and Visual Science, vol. 54, no. 3, pp. 2225-2237, 2013.
70. J. H. Kam, E. Lenassi, and G. Jeffery, "Viewing ageing eyes: diverse sites of amyloid beta accumulation in the ageing mouse retina and the up-regulation of macrophages," PLoS ONE, vol. 5, no. 10, Article ID e13127, 2010.
71. T. Yoshida, K. Ohno-Matsui, S. Ichinose et al., "The potential role of amyloid β in the pathogenesis of age-related macular degeneration,"The Journal of Clinical Investigation, vol. 115, no. 10, pp. 2793-2800, 2005.
72. K. H. Kurji, J. Z. Cui, T. Lin et al., "Microarray analysis identifies changes in inflammatory gene expression in response to amyloid-β stimulation of cultured human retinal pigment epithelial cells," Investigative Ophthalmology and Visual Science, vol. 51, no. 2, pp. 1151-1163, 2010.
73. M. T. Heneka,M. P. Kummer,A. Stutz et al., "NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice," Nature, vol. 493, no. 7434, pp. 674-678, 2013.
74. N. Murphy, B. Grehan, and M. A. Lynch, "Glial uptake of amyloid beta induces NLRP3 inflammasome formation via cathepsin-dependent degradation of NLRP10," NeuroMolecular Medicine, vol. 16, no. 1, pp. 205-215, 2014.
75. F. Schütt, M. Bergmann, F. G. Holz, and J. Kopitz, "Isolation of intact lysosomes from human RPE cells and effects of A2-E on the integrity of the lysosomal and other cellular membranes," Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 240, no. 12, pp. 983-988, 2002.
76. J. G. Hollyfield, V. L. Bonilha, M. E. Rayborn et al., "Oxidative damage-induced inflammation initiates age-related macular degeneration," Nature Medicine, vol. 14, no. 2, pp. 194-198, 2008.
77. H. Kaneko, S. Dridi, V. Tarallo et al., "DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration," Nature, vol. 471, no. 7338, pp. 325-332, 2011.
78. C. W. Schmid, "Does SINE evolution preclude Alu function?" Nucleic Acids Research, vol. 26, no. 20, pp. 4541-4550, 1998.
79. E. Bernstein, A. A. Caudy, S. M. Hammond, and G. J. Hannon, "Role for a bidentate ribonuclease in the initiation step of RNA interference," Nature, vol. 409, no. 6818, pp. 363-366, 2001.
80. P. D. Mariner, R. D. Walters, C. A. Espinoza et al., "Human Alu RNA is a modular transacting repressor ofmRNA transcription during heat shock," Molecular Cell, vol. 29, no. 4, pp. 499-509, 2008.
81. G. Lev-Maor, R. Sorek, N. Shomron, andG. Ast, "The birthof an alternatively spliced exon: 3' splice-site selection in Alu exons," Science, vol. 300, no. 5623, pp. 1288-1291, 2003.
82. S. M. Belgnaoui, R. G. Gosden, O. J. Semmes, and A. Haoudi, "Human LINE-1 retrotransposon induces DNA damage and apoptosis in cancer cells," Cancer Cell International, vol. 6, article 13, 2006.
83. P. Yi, W. Zhang, Z. Zhai, L. Miao, Y. Wang, and M. Wu, "Bclrambo beta, a special splicing variant with an insertion of an Alu-like cassette, promotes etoposide- and Taxol-induced cell death," FEBS Letters, vol. 534, no. 1-3, pp. 61-68, 2003.
84. Y. Kim, V. Tarallo, N. Kerur et al., "DICER1/Alu RNA dysmetabolism induces Caspase-8-mediated cell death in agerelated macular degeneration," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 45, pp. 16082-16087, 2014.
85. S. Janssens and R. Beyaert, "A universal role for MyD88 in TLR/IL-1R-mediated signaling," Trends in Biochemical Sciences, vol. 27, no. 9, pp. 474-482, 2002.
86. P. Dupraz, S. Cottet, F. Hamburger, W. Dolci, E. Felley-Bosco, and B. Thorens, "Dominant negative MyD88 proteins inhibit interleukin-1β/interferon-γ-mediated induction of nuclear factor κB-dependent nitrite production and apoptosis in β cells," The Journal of Biological Chemistry, vol. 275, no. 48, pp. 37672-37678, 2000.
87. A. O. Aliprantis, R.-B. Yang, D. S. Weiss, P. Godowski, and A. Zychlinsky, "The apoptotic signaling pathway activated by Tolllike receptor-2," The EMBO Journal, vol. 19, no. 13, pp. 3325-3336, 2000.
88. G. López-Castejón and P. Pelegrín, "Current status of inflammasome blockers as anti-inflammatory drugs," Expert Opinion on Investigational Drugs, vol. 21, no. 7, pp. 995-1007, 2012.
89. D. Arnoult, F. Soares, I. Tattoli, and S. E. Girardin, "Mitochondria in innate immunity," The EMBO Reports, vol. 12, no. 9, pp. 901-910, 2011.
90. F.-Q. Liang and B. F. Godley, "Oxidative stress-induced mitochondrial DNA damage in human retinal pigment epithelial cells: a possible mechanism for RPE aging and age-related macular degeneration," Experimental Eye Research, vol. 76, no. 4, pp. 397-403, 2003.
91. M. Cristina Kenney, M. Chwa, S. R. Atilano et al., "Inherited mitochondrial DNA variants can affect complement, inflammation and apoptosis pathways: insights into mitochondrialnuclear interactions," HumanMolecular Genetics, vol. 23, no. 13, pp. 3537-3551, 2014.
92. M. C. Kenney, M. Chwa, S. R. Atilano et al., "Mitochondrial DNA variantsmediate energy production and expression levels for CFH, C3 and EFEMP1 genes: implications for age-related macular degeneration," PLoS ONE, vol. 8, no. 1, Article ID e54339, 2013.
93. D. Malik, T. Hsu, P. Falatoonzadeh et al., "Human retinal transmitochondrial cybrids with J or H mtDNA haplogroups respond differently to ultraviolet radiation: implications for retinal diseases," PloSONE, vol. 9, no.6,Article IDe99003, 2014.
94. J.-M. Bruey, N. Bruey-Sedano, F. Luciano et al., "Bcl-2 and Bcl- XL regulate proinflammatory caspase-1 activation by interaction with NALP1," Cell, vol. 129, no. 1, pp. 45-56, 2007.
95. K. Shimada, T. R. Crother, J. Karlin et al., "Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis," Immunity, vol. 36, no. 3, pp. 401-414, 2012.
96. K. E. Lawlor, A. van Nieuwenhuijze, K. L. Parker et al., "Bcl-2 overexpression ameliorates immune complex-mediated arthritis by altering FcgammaRIIb expression and monocyte homeostasis," Journal of Leukocyte Biology, vol. 93, no. 4, pp. 585-597, 2013.
97. K. Nakahira, J. A. Haspel, V. A. K. Rathinam et al., "Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome," Nature Immunology, vol. 12, no. 3, pp. 222-230, 2011.
98. R. Zhou, A. Tardivel, B. Thorens, I. Choi, and J. Tschopp, "Thioredoxin-interacting protein links oxidative stress to inflammasome activation," Nature Immunology, vol. 11, no. 2, pp. 136-140, 2010.
99. F. Meissner, K. Molawi, and A. Zychlinsky, "Superoxide dismutase 1 regulates caspase-1 and endotoxic shock," Nature Immunology, vol. 9, no. 8, pp. 866-872, 2008.
100. F. L. van de Veerdonk, S. P. Smeekens, L. A. B. Joosten et al., "Reactive oxygen species-independent activation of the IL-1β inflammasome in cells from patients with chronic granulomatous disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 7, pp. 3030-3033, 2010.
101. F. Meissner, R. A. Seger,D. Moshous, A. Fischer, J. Reichenbach, and A. Zychlinsky, "Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease," Blood, vol. 116, no. 9, pp. 1570-1573, 2010.
102. A. Rubartelli, "Redox control of NLRP3 inflammasome activation in health and disease," Journal of Leukocyte Biology, vol. 92, no. 5, pp. 951-958, 2012.
103. K. Minton, "Inflammasomes: ubiquitin lines up for inflammasome activity," Nature Reviews Immunology, vol. 14, no. 9, pp. 580-581, 2014.
104. S. Mirza, K. S. Plafker, C. Aston, and S. M. Plafker, "Expression and distribution of the class III ubiquitin-conjugating enzymes in the retina," Molecular Vision, vol. 16, pp. 2425-2437, 2010.
105. X. Zhang, J. Zhou, A. F. Fernandes et al., "The proteasome: a target of oxidative damage in cultured human retina pigment epithelial cells," Investigative Ophthalmology & Visual Science, vol. 49, no. 8, pp. 3622-3630, 2008.
106. J. E. Ramos de Carvalhol, I. Klaassen, I. M. C. Vogels et al., "Complement factor C3a alters proteasome function in human RPE cells and in an animalmodel of age-related RPE degeneration," Investigative Ophthalmology and Visual Science, vol. 54, no. 10, pp. 6489-6501, 2013.
107. J. V. Glenn, H. Mahaffy, S. Dasari et al., "Proteomic profiling of human retinal pigment epithelium exposed to an advanced glycation-modified substrate," Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 3, pp. 349-359, 2012.
108. T. Bergsbaken, S. L. Fink, and B. T. Cookson, "Pyroptosis: host cell death and inflammation," Nature ReviewsMicrobiology, vol. 7, no. 2, pp. 99-109, 2009.
109. S. B. Bressler and N. M. Bressler, "Age-related macular degeneration: non-neovascular early AMD, intermediate AMD, and geographic atrophy," in Retina, S. J. Ryan, Ed., pp. 1150-1182, Elsevier, 5th edition, 2014.
110. J. P. Sarks, S. H. Sarks, and M. C. Killingsworth, "Evolution of geographic atrophy of the retinal pigment epithelium," Eye, vol. 2, no. 5, pp. 552-577, 1988.
111. H. Gao and J. G. Hollyfield, "Aging of the human retina: differential loss of neurons and retinal pigment epithelial cells," Investigative Ophthalmology & Visual Science, vol. 33, no. 1, pp. 1-17, 1992.
112. S. S. Iyer,W. P. Pulskens, J. J. Sadler et al., "Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome," Proceedings of the National Academy of Sciences of the United States ofAmerica, vol. 106, no.48, pp.20388-20393,2009.
113. A. M. Newman, N. B. Gallo, L. S. Hancox et al., "Systemslevel analysis of age-related macular degeneration reveals global biomarkers and phenotype-specific functional networks," Genome Medicine, vol. 4, no. 2, article 16, 2012.